Abstract: A compound of the structure ##STR1## wherein R.sup.1 and R.sup.2 are each, independently, hydrogen or ##STR2## R.sup.3 is a mono-, di-, poly-, or per-fluorinated alkyl group with the proviso that R.sup.1 and R.sup.2 are both not hydrogen, which by virtue of its immunosuppressive activity is useful in treating transplantation rejection, host vs. graft disease, autoimmune diseases and diseases of inflammation; by virtue of its antitumor activity is useful in treating solid tumors; and by virtue of its antifungal activity is useful in treating fungal infections.

Abstract: There is disclosed a method for the treatment of immunoinflammatory conditions, such as allergy, anaphylaxis, asthma, psoriasis, inflammatory bowel disease and inflammation in mammals which comprises administering to a mammal so afflicted an effective amount of a compound having the formula: ##STR1## wherein Z is a group having the formula ##STR2## R.sup.1 and R.sup.2 are each, independently, hydrogen or lower alkyl; R.sup.3 and R.sup.4 are each, independently, hydrogen, alkyl of 1-20 carbon atoms, halo, halo lower alkyl, halo lower alkoxy, lower alkoxy, halo lower alkylsulfonyl, nitro or trifluoromethyl, where at least one of R.sup.3 and R.sup.4 is other than hydrogen;R.sup.5 is hydrogen, lower alkyl or halo;A is --CH.sub.2 --, --O-- or --S--;m is 0-10;n is 1-8;X is hydrogen, fluoro, lower alkyl or aralkyl of 7-12 carbon atoms;or a pharmacologically acceptable salt thereof.

Abstract: There are disclosed compounds of the formula ##STR1## wherein R.sup.1 and R.sup.2 taken together represent ##STR2## R.sup.3 and R.sup.4 are hydrogen; R.sup.5 is 2-pyridinyl, 2-pyrazinyl, 2-pyrimidinyl, 3-pyridazinyl or any of the foregoing R.sup.5 moieties substituted by lower alkyl, lower alkoxy, halo lower alkyl, cyano, nitro or halo;X, Y and Z are, independently, N, S, O, NR.sup.6, SO, SO.sub.2, CR.sup.6 or CH.sub.2 ;A is lower alkylene, O or S;R.sup.6 is hydrogen, lower alkyl, aryl, aralkyl;m is 3-7;and the pharmaceutically acceptable salts thereof, and their use as antipsychotic/-anxiolytic agents having a low liability for extrapyramidal side effects.

Abstract: There are disclosed compounds of the formula ##STR1## wherein R.sup.1 and R.sup.2 are each, independently, hydrogen, lower alkyl, aryl or halo, or R.sup.1 and R.sup.2 taken together represent ##STR2## where the dotted lines represent optional double bonds; R.sup.3, R.sup.4 and R.sup.5 are each, independently, hydrogen, lower alkyl, aryl or halo;R.sup.6 is 2-pyridinyl, 2-pyrazinyl, 2-quinolyl, 2-quinoxalinyl or any of the foregoing R.sup.6 moieties substituted by lower alkyl, lower alkoxy, trifluoromethyl, cyano, nitro or halo; or ##STR3## wherein R.sup.7 is phenyl, 2-pyridinyl, 2-pyrimidinyl, 3-pyridazinyl or 2-pyrazinyl or any of the foregoing R.sup.7 moieties substituted by lower alkyl, lower alkoxy, halo, cyano, trifluoromethyl or nitro;Z is ##STR4## X is lower alkylene, vinylene, O or NH; m is 1-5;n is 0-4;p is 1-4;q is 1-2;and the pharmaceutically acceptable salts thereof, and their use as antipsychotic/anxiolytic agents having a low liability for extrapyramidal side effects.

Abstract: There is disclosed a method for the treatment of immunoinflammatory conditions, such as allergy, anaphylaxis, asthma and inflammation in mammals which comprises administering to a mammal so afflicated an effective amount of a compound having the formula: ##STR1## wherein R.sup.1 and R.sup.2 are each, independently, hydrogen, hydroxy, lower alkyl, lower alkoxy, haloloweralkyl, haloloweralkyl sulfonyl, halo or nitro;R.sup.3 is hydrogen, lower alkyl, or aryl of 7-12 carbon atoms;X is ##STR2## A is --CH.sub.2 --, --O-- or --S--; m is 0-8;n is 0-7, with the proviso that m+n.ltoreq.8;or a pharmacologically acceptable salt thereof.

Abstract: There are disclosed compounds of the formula ##STR1## wherein R.sup.1 and R.sup.2 are each, independently, hydrogen, lower alkyl, aryl or halo, or R.sup.1 and R.sup.2 taken together represent ##STR2## where the dotted lines represent optional double bonds; R.sup.3, R.sup.4 and R.sup.5 are each, independently, hydrogen, lower alkyl, aryl or halo;R.sup.6 is 2-pyridinyl, 2-pyrazinyl, 2-quinolyl, 2-quinoxalinyl or any of the foregoing R.sup.6 moieties substituted by lower alkyl, lower alkoxy, trifluoromethyl, cyano, nitro or halo; orR.sup.6 is ##STR3## wherein R.sup.7 is phenyl, 2-pyridinyl, 2-pyrimidinyl, 3-pyridazinyl or 2-pyrazinyl or any of the foregoing R.sup.7 moieties substituted by lower alkyl, lower alkoxy, halo, cyano, trifluoromethyl or nitro;Z is --(CH.sub.2).sub.

Abstract: There are disclosed compounds of the formula ##STR1## wherein R.sup.1 and R.sup.2 are each, independently, hydrogen, hydroxy, lower alkyl, lower alkoxy, haloloweralkyl, haloloweralkyl sulfonyl, halo or nitro;R.sup.3 is hydrogen, lower alkyl, or aryl of 7-12 carbon atoms; ##STR2## A is --CH.sub.2 --, --O-- or --S--; m is 1-8;n is 0-7, with the proviso that m+n.ltoreq.8;or a pharmacologically acceptable salt thereof, and their use as fatty acid oxidation inhibitors possessing a significantly reduced potential for impairment of normal cardiac function, and having particular utility in the treatment of glucose and fatty acid metabolism disorders, such as diabetes.

Abstract: There is disclosed a method for the treatment of immunoinflammatory conditions, such as allergy, anaphylaxis, asthma and inflammation in mammals which comprises administering to a mammal so afflicted an effective amount of a compound having the formula: ##STR1## wherein R.sup.1 and R.sup.2 are each, independently, hydrogen, hydroxy, lower alkyl, lower alkoxy, haloloweralkyl, haloloweralkyl sulfony., halo or nitro;R.sup.3 is hydrogen, lower alkyl, or aryl of 7-12 carbon atoms;X is ##STR2## A is --CH.sub.2 --,--O-- or --S--; m is 0-8;n is 0-7, with the proviso that m+n.ltoreq.

Abstract: A compound of the formula: ##STR1## in which A is a 3,4-; 3,2-; or 2,3-fused thieno- moiety or a benzo- moiety;X is alkylene of 2 to 5 carbon atoms;R.sup.1 is hydrogen, bromo or methyl;R.sup.2 is methoxy when R.sup.1 is hydrogen, methyl when R.sup.1 is bromo, and bromo when R.sup.1 is methyl;R.sup.3 is hydrogen or alkyl of 1 to 6 carbon atoms;R.sup.4 is hydrogen or alkyl of 1 to 6 carbon atoms;R.sup.3 and R.sup.4, taken together, are ethylene when X is ethylene;R.sup.5 is hydrogen when A is thieno, and when A is benzo, R.sup.5 is hydrogen, alkyl of 1 to 6 carbon atoms, halo or alkoxy of 1 to 6 carbon atoms;R.sup.6 is hydrogen when A is thieno, and when A is benzo, R.sup.

Abstract: Substituted imides of the following formulae are antipsychotic, anxiolytic agents with very little extrapyramidal side effects: ##STR1## in which n is one of the integers 2, 3, 4 or 5; R is phenyl, halophenyl, trifluoromethylphenyl, alkoxyphenyl in which the alkoxy substituent contains 1 to 3 carbon atoms, 2-pyrimidinyl halopyrimidin-2-yl, 2-pyrazinyl, halopyrazin-2-yl, 2-pyridinyl, halopyridin-2-yl, cyanopyridin-2-yl, quinolyl, or haloquinolyl; and the dotted lines represent optional unsaturation; or a pharmaceutically acceptable salt thereof.

Abstract: There are disclosed compounds of the formula ##STR1## wherein R.sup.1 and R.sup.2 are each, independently, hydrogen, lower alkyl, aryl or halo, or R.sup.1 and R.sup.2 taken together represent --CH.sub.2 --, --CH.sub.2 CH.sub.2 --, --O--, --NH--, ##STR2## where the dotted lines represent optional double bonds; R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are each, independently, hydrogen, lower alkyl, aryl or halo;R.sup.7 is 2-pyridinyl, 2-pyrimidinyl, 2-pyrazinyl, 3-pyridazinyl or phenyl or any of the foregoing R.sup.7 moieties substituted by lower alkyl, trifluoromethyl, cyano, nitro or halo, with the proviso that when R.sup.1 and R.sup.2 taken together represent ##STR3## then R.sup.7 is other than 2-pyridinyl, 2-pyrimidinyl or substituted pyrimidin-2-yl;Z is --(CH.sub.2).sub.

Abstract: There are disclosed compounds of the formula ##STR1## wherein R.sup.1 and R.sup.2 are each, independently, hydrogen or lower alkyl, or R.sup.1 and R.sup.2 taken together represent ##STR2## A is O or NR.sup.3 ; B is --(CH.sub.2).sub.n --, ##STR3## R.sup.3 is hydrogen or lower alkyl; R.sup.4 is hydrogen, lower alkyl, aryl of 6-12 carbon atoms or halo;R.sup.5 is unsubstituted or substituted phenyl, 2-pyridinyl, 2-pyrimidinyl, 2-pyrazinyl or 3-pyridazinyl, where the substituents are selected from the group lower alkyl, lower alkoxy, halo, cyano, nitro and trifluoromethyl;Z is --(CH.sub.2).sub.n -- or vinylene;X is lower alkylene, vinylene or O;m is 2-5;n is 1-3;o is 1-5;and the pharmaceutically acceptable salts thereof and their use as antipsychotic/anxiolytic agents having a low liability for extrapyramidal side effects.

Abstract: A process for preparing certain thieno-fused heterocyclic compounds having H.sub.2 -receptor antagonist and antisecretory activity, which involves the reaction of a mercaptan, obtained by reduction of a thienoisothiazole amino alkyl disulfide, with a 5-substituted-2-furanylmethanol; and said thienoisothiazole amino alkyl disulfide intermediates.

Abstract: Compounds of the formula ##STR1## wherein R.sup.1 is ##STR2## wherein B is a moiety having the formula ##STR3## R is H, mono- or dihalo, amino, nitro, cyano, hydroxy, trifuoromethyl, mercapto, lower alkyl, lower alkoxy, alkanoyl, lowercycloalkyl, carboxy, alkoxycarbonyl, mono- or di-lower alkyl substituted amino, alkanoylamino, lower alkyl thio, loweralkylsulfonyl, sulfamoyl, lower alkyl substituted sulfamoyl, phenyl or phenyl substituted with halo, lower alkyl, lower alkoxy, trifluoromethyl, hydroxy, amino, cyano or nitro;X is SO.sub.2, SO, S or C.dbd.O; andR.sup.2 is phenyl or 1,3-benzodioxol-5-yl;and the pharmacologically acceptable salts thereof, which are (H.sup.+ +K.sup.+)ATPase inhibitors exhibiting a cytoprotective action, are useful in the treatment of conditions where there is hypersecretion of gastric acid, such as gastric and peptic ulceration, as well as in conditions such as stress ulceration.

Abstract: A process for preparing certain thieno-fused heterocyclic compounds having H.sub.2 -receptor antagonist and antisecretory activity, which comprises reacting a suitable thienoisothiazole derivative with an appropriate (furanylmethylthio)ethanamine derivative to yield an intermediate, which is subjected to cyclization to yield the desired final product.

Abstract: Compounds of the formula: ##STR1## wherein B is a moiety having the formula: ##STR2## R is mono- or dihalo, amino, nitro, cyano, hydroxy, trifluoromethyl, mercapto, lower alkyl, lower alkoxy, alkanoyl, cycloalkyl of 4-7 carbon atoms, carboxy, alkoxycarbonyl, mono- or di-lower alkyl substituted amino, alkanoylamino, lower alkyl thio, lower alkylsulfonyl, sulfamoyl, lower alkyl substituted sulfamoyl, phenyl or phenyl substituted with halo, lower alkyl, lower alkoxy, trifluoromethyl, hydroxy, amino, cyano or nitro.X is SO.sub.2, SO, S or C.dbd.O; andA is amine selected from the group ##STR3## , wherein R.sup.1 is hydrogen or R.sup.2 CH.sub.2 wherein R.sup.2 is mono- or diloweralkylamino, mono- or di-N-lower alkylaminoloweralkyl, (2-furyl)methylamino, benzylamino, lowercycloalkylamino, 1-pyrrolidinyl, 1-piperidinyl, 1-hexahydroazepinyl, 1-octahydroazocinyl, 3-thiazolidinyl, 4-morpholinyl or 4-thiomorpholinyl; R.sup.3 is hydrogen or (1-piperidinyl)methyl with the proviso that when R.sup.

Abstract: Compounds of the formula: ##STR1## wherein X is SO.sub.2, SO or S; andA is an amine selected from the group: ##STR2## wherein R is hydrogen, (lower)alkyl, (lower)alkoxy or halo; n is 2-4; andthe pharmacologically acceptable salts thereof are disclosed.